Aromatase inhibitors and inactivators for breast cancer therapy

Drugs and Aging

Volumn 19, Issue 4, 2002, Pages 277-298

  Lønning, Per E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; GESTAGEN; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL; TAMOXIFEN; TESTOLOLACTONE; TRASTUZUMAB; XENOBIOTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ESTROGEN SYNTHESIS; HUMAN; META ANALYSIS; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0036293783     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219040-00003     Document Type: Review

References (218)

1. Castration for primary inoperable or recurrent breast carcinoma
2. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
3. Relationship between the progesterone, androgen, and glucocorticoid receptor and response rate to endocrine therapy in metastatic breast cancer
4. Improved measurement of androgen receptors in human breast cancer
5. Progestins in breast cancer treatment
6. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer II: A differential effect of megestrol acetate on serum estrone sulfate and sex hormone binding globulin
7. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-I. General findings
8. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients
9. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study
10. The endocrine effects of long-term treatment with mifepristone (RU 486)
11. Influence of treatment with onapristone on the IGF-system in breast cancer patients
12. Androgens and estrogens in the treatment of disseminated mammary carcinoma
13. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha
14. From estrogen to androgen receptor: A new pathway for sex hormones in prostate
15. Role of androgens in breast cancer
16. Role of the androgen receptor in human breast cancer
17. Cloning of a novel receptor expressed in rat prostate and ovary
18. ER ß identification and characterization of a novel human estrogen receptor
19. Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer
20. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer
21. Differential ligand activation of estrogen receptors ER alpha and ER beta at APl sites
22. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
23. Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions
24. Resistance to endocrine therapy of breast cancer: Recent advances and tomorrows challenges
25. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
26. erbB-2 amplification is associated with tamoxifen resistance in steroid receptor positive breast cancer
27. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
28. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
29. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and /or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomised trial
30. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
31. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer
32. Influence of tamoxifen on the plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients
33. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer
34. Endocrine activity of the postmenopausal ovary: The effects of pituitary down-regulation and oophorectomy
35. The postmenopausal ovary is not a major androgen-producing gland
36. Aromatization of androstenedione by isolated human hairs
37. Aromatization of androstenedione by cultured human fibroblasts
38. Human fatty marrow aromatizes androgen to estrogen
39. The interconversion and aromatization of androgens by human adipose tissue
40. Aromatization of androstenedione by human adult liver in vitro
41. Aromatization by skeletal muscle
42. Androgen and estrogen dynamics in pre- and postmenopausal women: A comparison between smokers and nonsmokers
43. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
44. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
45. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
46. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route
47. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients
48. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
49. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients
50. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients
51. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors
52. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer
53. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings
54. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide
55. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition
56. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study
57. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
58. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
59. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity
60. The potential for aromatase inhibition in breast cancer prevention
61. Endogenous oestradiol-17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: Relationship to receptor content
62. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue
63. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
64. Neoadjuvant treatment with anastrozole ('Arimidex') causes profound suppression of intra-estrogen levels
65. Estrone and estradiol content in human breast tumors: Relationship to estradiol receptors
66. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome p450 transcripts using competitive polymerase chain reaction after reverse transcription
67. Aromatase activity in primary and metastatic human breast cancer
68. Relationship between tumour aromatase activity, tumour characteristics and response to therapy
69. In situ oestrone synthesis in normal breast and breast tumour tissue; effect of treatment with 4-hydroxyandrostenedione
70. Aromatase in human breast carcinoma
71. Intratumoral aromatase as a prognostic factor in human breast carcinoma
72. Immunolocalization of aromatase in human breast disorders using different antibodies
73. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts
74. Aromatase expression in the human breast
75. Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas
76. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake
77. Breast tumor aromatase: Functional role and transcriptional regulation
78. The regulation of aromatase activity in breast fibroblasts: The role of interleukin-6 and prostaglandin E2
79. Importance of intratumour aromatase, and its susceptibility to inhibitors
80. Long term estrogen deprivation (LTED) enhances aromatase activity in breast cancer cells
81. Antiaromatase agents: Preclinical data and neoadjuvant therapy
82. Aromatase activity and interleukin-6 production by normal and malignant breast tissues
83. Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors
84. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4
85. Mechanism of human placental aromatase, a new active site model
86. A detailed molecular modal for human aromatase
87. A three-dimensional model of aromatase cytochrome p450
88. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase
89. Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes
90. Use of alternative promoters to express the aromatase cytochrome p450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients
91. Estrogen biosynthesis in adipose tissue: Regulation by paracrine and autocrine mechanisms
92. Do intracrine mechanisms regulate aromatase expression?
93. Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor
94. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo
95. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer
96. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients
97. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
98. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer
99. Aromatase inhibitors in the treatment of advanced breast cancer
100. Aminoglutethimide enzyme induction: Pharmacological and endocrinological implications
101. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
102. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients
103. Inhibition of aromatase with cgs 16949a in postmenopausal women
104. Pharmacokinetics of new aromatase inhibitor CGS 20267
105. Arimidex: A potent and selective fourth-generation aromatase inhibitor
106. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
107. Aromatase inhibitors: Synthesis, biological activity, and binding mode of azole-type compounds
108. The preclinical pharmacology of 'Arimidex' (anastrozole; ZD1033) -a potent, selective aromatase inhibitor
109. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients
110. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors
111. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor
112. 4-Aminoandrostenedione derivatives, a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione
113. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study
114. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: A phase I study
115. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients
116. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report
117. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
118. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
119. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue
120. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole
121. Stepwise estrogen suppression manipulating the estrostat
122. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer
123. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection
124. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection
125. HPLC enantiomeric resolution of novel aromatase inhibitors on cellulose- and amylose-based chiral stationary phases under reversed phase mode
126. Absolute bioavailability of letrozole in healthy postmenopausal women
127. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration
128. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women
129. Arimidex (ZD 1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers
130. Exemestane experience in breast cancer treatment
131. Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide
132. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
133. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer
134. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer
135. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
136. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial
137. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
138. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer
139. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer
140. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomised cross-over trial
141. Megestrol acetate versus aminoglutethimide for metastatic breast cancer
142. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma
143. Aromatase inhibition: Past, present and future
144. A dose response evaluation of delta-1-testololactone in advanced breast cancer
145. In vivo effects of delta 1-testololactone on peripheral aromatization
146. Testololactone: Clinical trials
147. Formestane: A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer
148. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients
149. An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients
150. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)
151. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex (R)) with intramuscular formestane in postmenopausal women with advanced breast cancer
152. Aromatase inhibition with 4-OHandrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
153. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: Clinical and endocrine effects
154. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
155. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
156. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma
157. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer
158. Fadrozole HCl (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multi-institutional trials
159. Fadrozole versus megestrol acetate: A double-blind randomised trial in advanced breast cancer
160. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
161. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer -prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
162. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
163. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
164. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
165. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
166. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
167. Exemestane is superior to megestrol acetate after tamoxifen failure in post-menopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
168. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
169. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
170. Anastrozole vs tamoxifen in hormonodependent advanced breast cancer: A phase II randomized trial
171. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
172. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organization for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn
173. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
174. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen and megace
175. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
176. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
177. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
178. Formestane (FOR) a steroidal aromatase inhibitor (SAI) after failure of nonsteroidal aromatase inhibitors (nSAI)(anastrozole: ANZ and letrozole: LTZ): Is a clinical benefit (CB) still possible?
179. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
180. A phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam)
181. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
182. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel
183. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
184. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
185. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
186. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer
187. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy
188. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
189. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture
190. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
191. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo
192. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
193. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey
194. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
195. Serum sex hormone levels after menopause and subsequent breast cancer
196. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
197. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal (PM) women
198. Prevention and management of osteoporosis. Current trends and future prospects
199. Selective oestrogen receptor modulators: Potential therapeutic applications
200. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women
201. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
202. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
203. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen
204. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
205. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
206. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
207. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
208. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
209. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women -a 2-year, placebo-controlled study
210. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -results from a 3-year randomized clinical trial
211. Relation between apolipoprotein E phenotype and the changes in lipids during tamoxifen treatment
212. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
213. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen
214. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
215. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
216. Effect of nonsteroidal aromatase inhibitors (AI) on serum lipids profile in patients with breast cancer. Preliminary report
217. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
218. No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin (R) (exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): Companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacias Upjohn